We are live on ! Find out more
DWTX icon

Dogwood Therapeutics

25 hedge funds and large institutions have $181K invested in Dogwood Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

47% more capital inflows, than outflows

Capital inflows: $46.3K | Capital outflows: $31.5K

4% more funds holding

Funds holding: 24 → 25 (+1)

0.29% more ownership

Funds ownership: 3.55% → 3.84% (+0.29%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

DWTX Hedge Fund Activity: Q3 2024 in Review

25 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q3 2024, worth a combined $181K — down 15% from $212K a quarter earlier.

Fund positioning in DWTX was balanced in Q3 2024: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 3 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $11.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $14.2K sold.

  • 25 institutional investors held Dogwood Therapeutics (DWTX) as of Q3 2024, up from 24 in Q2 2024.
  • Funds reported $181K of Dogwood Therapeutics stock for Q3 2024, down 15% quarter-over-quarter.
  • 4 funds opened new Dogwood Therapeutics positions in Q3 2024 and 4 closed out, a net change of 0 holders.
  • The largest Dogwood Therapeutics buyer in Q3 2024 was Geode Capital Management, an estimated $11.7K added.
  • The largest Dogwood Therapeutics seller in Q3 2024 was Susquehanna International Group, an estimated $14.2K sold.

Based on aggregated 13F filings for Q3 2024.